ResMed studies show efficacy of PAP therapy
By HME News Staff
Updated 1:53 PM CDT, Thu May 23, 2024
SAN DIEGO – New ResMed-supported research providing insights into the effectiveness of PAP therapy in treating sleep-disordered breathing and its associated clinical benefits was presented at the American Thoracic Society International Conference.
The studies were among a total of 26 supported by ResMed in collaboration with leading scientists, including Michael Arzt, MD, Universitätsklinikum Regensburg, Germany; Jean-Louis Pépin, MD, Grenoble Alpes University, France; Atul Malhotra, MD, University of California, San Diego; and Holger Woehrle, Ulm Lung Centre, Germany.
Highlights include:
-
An analysis of data from 27 randomized control trials and non-randomized control studies on the effects of PAP on patients with OSA found mortality was 37% lower on average in patients with PAP-treated OSA vs. untreated OSA.
-
One study looked at nearly 50,000 adults with COPD who were treated via domiciliary NIV and found long-term home use of NIV was strongly associated with a reduced risk of death.
-
Another study projected OSA cases in the United States to increase by 27.6% by 2050 in men and women aged 30-70, with an overall prevalence within this group projected to be 26%.
-
Another study found GLP-1s did not lead to higher discontinuation rates of PAP therapy, rather to higher levels of PAP therapy use.
Comments